2 results
Not approvedWill not start
Primary:To compare the efficacy of abrocitinib 200 mg once daily (QD) versus dupilumab (as per label guidelines) in adult participants on background topical therapy with moderate to severe atopic dermatitis (AD).Key SecondaryTo compare the efficacy…
Approved WMOPending
The primary aim of the study is to evaluate whether treatment with the EKOS device on top of anticoagulation in patients with severe pulmonary embolism results in a better clinical outcome than treatment with anticoagulation alone. The primary…